Which are the major pathogenetic mechanisms in Viral hepatitis C?
Which are the long term clinical outcomes after definitive eradication of the hepatitis C virus by antiviral therapy?
How metabolic factors and diet contribute to the pathogenesis of esophageal cancer?
We are interested in defining pathogenetic mechanisms and clinical outcomes in hepatitis C, with specific focus on direct antiviral agents. This is approached by prospective studies in a large cohort of HCV patients which are currently followed up in the Veneto Region.
We are also investigating pathogenetic and metabolic mechanisms in the development of esophageal cancers, using a combination of animal models and human materials derived from patients at different pre-neoplastic and neoplastic stages.
- Full Professor of Gastroenterology, Department of Molecular Medicine, University of Padova, Italy (current)
- MD: University of Padova (1972)
- Post-graduate degree in Hematology – University of Padova, Italy (1976)
- Post-graduate degree in Gastroenterology – University of Padova, Italy (1984)
- Visiting Professor – King’s College – London (1976-1979)
- Group leader: Institute of Internal Medicine – University of Padova, Italy (since 1990)
- Venetian Institute of Molecular Medicine, Padova, Italy (since 2001)
- NIH Panel on hepatitis C (1997 and 2002)
- NIH Consensus Panel on Hepatitis B (2000)
- WHO Viral Hepatitis task Force (2001-2006)
- 2000 – Romania Medical Association Award
- 2002 – Japanese Society of Gastroenterology Award
- 2003 – Jordanian Gastroenterology Award
- 2017 – Career Award for Hepatology – AISF